Human cytomegalovirus UL40 signal peptide regulates cell surface expression of the NK cell ligands HLA-E and gpUL18

Journal of Immunology

Volumn 188, Issue 6, 2012, Pages 2794-2804

  Prod'homme, Virginie ^a   Tomasec, Peter ^a   Cunningham, Charles ^b   Lemberg, Marius K ^c   Stanton, Richard J ^a   McSharry, Brian P ^a   Wang, Eddie C Y ^a   Cuff, Simone ^a   Martoglio, Bruno ^d   Davison, Andrew J ^b   Braud, Véronique M ^e   Wilkinson, Gavin W G ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b MRC UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH   (United Kingdom)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

^e INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN GPUL18; HLA E ANTIGEN; PEPTIDE UL40; SIGNAL PEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL MATURATION; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOMEGALOVIRUS; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNE EVASION; IMMUNOMODULATION; LIGAND BINDING; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SPUL40 GENE; TRANSCRIPTION INITIATION SITE; UPREGULATION; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS GENOME; VIRUS STRAIN;

AMINO ACID SEQUENCE; BLOTTING, NORTHERN; BLOTTING, WESTERN; CAPSID PROTEINS; CELL MEMBRANE; CELL SEPARATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNE EVASION; KILLER CELLS, NATURAL; MOLECULAR SEQUENCE DATA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRAL PROTEINS;

EID: 84857862484     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1102068     Document Type: Article

References (64)

1. Mocarski, E. S., T. Shenk, and R. F. Pass. 2007. Cytomegaloviruses. In Fields Virology, 5th ed. D. M. Knipe and P. M. Howley, eds. Lippincott, Williams &Wilkins, Philadelphia, p. 2701-2772.
2. Mocarski, E. S., Jr. 2002. Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol. 10: 332-339.
3. Wilkinson, G. W., P. Tomasec, R. J. Stanton, M. Armstrong, V. Prod'homme, R. Aicheler, B. P. McSharry, C. R. Rickards, D. Cochrane, S. Llewellyn-Lacey, et al. 2008. Modulation of natural killer cells by human cytomegalovirus. J. Clin. Virol. 41: 206-212.
4. Hansen, S. G., C. J. Powers, R. Richards, A. B. Ventura, J. C. Ford, D. Siess, M. K. Axthelm, J. A. Nelson, M. A. Jarvis, L. J. Picker, and K. Früh. 2010. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 328: 102-106.
5. Yokoyama, W. M., S. Kim, and A. R. French. 2004. The dynamic life of natural killer cells. Annu. Rev. Immunol. 22: 405-429. (Pubitemid 38680428)
6. Willcox, B. E., L. M. Thomas, and P. J. Bjorkman. 2003. Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor. Nat. Immunol. 4: 913-919. (Pubitemid 37098663)
7. Yang, Z., and P. J. Bjorkman. 2008. Structure of UL18, a peptide-binding viral MHC mimic, bound to a host inhibitory receptor. Proc. Natl. Acad. Sci. USA 105: 10095-10100.
8. Browne, H., G. Smith, S. Beck, and T. Minson. 1990. A complex between the MHC class I homologue encoded by human cytomegalovirus and beta 2 microglobulin. Nature 347: 770-772.
9. Fahnestock, M. L., J. L. Johnson, R. M. Feldman, J. M. Neveu, W. S. Lane, and P. J. Bjorkman. 1995. The MHC class I homolog encoded by human cytomegalovirus binds endogenous peptides. Immunity 3: 583-590.
10. Wagner, C. S., H. G. Ljunggren, and A. Achour. 2008. Immune modulation by the human cytomegalovirus-encoded molecule UL18, a mystery yet to be solved. J. Immunol. 180: 19-24.
11. Wagner, C. S., A. Rö lle, D. Cosman, H. G. Ljunggren, K. D. Berndt, and A. Achour. 2007. Structural elements underlying the high binding affinity of human cytomegalovirus UL18 to leukocyte immunoglobulin-like receptor-1. J. Mol. Biol. 373: 695-705.
12. Cosman, D., N. Fanger, L. Borges, M. Kubin, W. Chin, L. Peterson, and M. L. Hsu. 1997. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 7: 273-282. (Pubitemid 27392018)
13. Chapman, T. L., A. P. Heikeman, and P. J. Bjorkman. 1999. The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18. Immunity 11: 603-613.
14. Prod'homme, V., C. Griffin, R. J. Aicheler, E. C. Wang, B. P. McSharry, C. R. Rickards, R. J. Stanton, L. K. Borysiewicz, M. López-Botet, G.W. Wilkinson, and P. Tomasec. 2007. The human cytomegalovirus MHC class I homolog UL18 inhibits LIR-1+ but activates LIR-1 - NK cells. J. Immunol. 178: 4473-4481. (Pubitemid 46492399)
15. Tomasec, P., V. M. Braud, C. Rickards, M. B. Powell, B. P. McSharry, S. Gadola, V. Cerundolo, L. K. Borysiewicz, A. J. McMichael, and G. W. Wilkinson. 2000. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 287: 1031.
16. Braud, V. M., D. S. Allan, C. A. O'Callaghan, K. Söderström, A. D'Andrea, G. S. Ogg, S. Lazetic, N. T. Young, J. I. Bell, J. H. Phillips, et al. 1998. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391: 795-799. (Pubitemid 28099678)
17. Borrego, F., M. Ulbrecht, E. H. Weiss, J. E. Coligan, and A. G. Brooks. 1998. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J. Exp. Med. 187: 813-818. (Pubitemid 28115198)
18. Lee, N., D. R. Goodlett, A. Ishitani, H. Marquardt, and D. E. Geraghty. 1998. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J. Immunol. 160: 4951-4960. (Pubitemid 28215330)
19. Braud, V., E. Y. Jones, and A. McMichael. 1997. The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur. J. Immunol. 27: 1164-1169. (Pubitemid 27197219)
20. Lemberg, M. K., F. A. Bland, A. Weihofen, V. M. Braud, and B. Martoglio. 2001. Intramembrane proteolysis of signal peptides: an essential step in the generation of HLA-E epitopes. J. Immunol. 167: 6441-6446. (Pubitemid 33081577)
21. Weihofen, A., K. Binns, M. K. Lemberg, K. Ashman, and B. Martoglio. 2002. Identification of signal peptide peptidase, a presenilin-type aspartic protease. Science 296: 2215-2218. (Pubitemid 34680305)
22. Braud, V. M., D. S. Allan, D. Wilson, and A. J. McMichael. 1998. TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Curr. Biol. 8: 1-10. (Pubitemid 28056248)
23. Ulbrecht, M., S. Martinozzi, M. Grzeschik, H. Hengel, J. W. Ellwart, M. Pla, and E. H. Weiss. 2000. Cutting edge: the human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis. J. Immunol. 164: 5019-5022. (Pubitemid 30305172)
24. Wang, E. C., B. McSharry, C. Retiere, P. Tomasec, S. Williams, L. K. Borysiewicz, V. M. Braud, and G. W. Wilkinson. 2002. UL40-mediated NK evasion during productive infection with human cytomegalovirus. Proc. Natl. Acad. Sci. USA 99: 7570-7575. (Pubitemid 34568732)
25. Gumá, M., A. Angulo, C. Vilches, N. Gómez-Lozano, N. Malats, and M. López- Botet. 2004. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 104: 3664-3671.
26. Gumá, M., M. Budt, A. Sáez, T. Brckalo, H. Hengel, A. Angulo, and M. López- Botet. 2006. Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood 107: 3624-3631.
27. Pietra, G., C. Romagnani, P. Mazzarino, M. Falco, E. Millo, A. Moretta, L. Moretta, and M. C. Mingari. 2003. HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes. Proc. Natl. Acad. Sci. USA 100: 10896-10901. (Pubitemid 37140124)
28. Lemberg, M. K., and B. Martoglio. 2002. Requirements for signal peptide peptidase-catalyzed intramembrane proteolysis. Mol. Cell 10: 735-744. (Pubitemid 35335630)
29. Wilkinson, G. W., and A. Akrigg. 1992. Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Res. 20: 2233-2239.
30. Stanton, R. J., B. P. McSharry, M. Armstrong, P. Tomasec, and G. W. Wilkinson. 2008. Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function. Biotechniques 45: 659-662, 664-668.
31. Kaye, J., H. Browne, M. Stoffel, and T. Minson. 1992. The UL16 gene of human cytomegalovirus encodes a glycoprotein that is dispensable for growth in vitro. J. Virol. 66: 6609-6615.
32. Browne, H., M. Churcher, and T. Minson. 1992. Construction and characterization of a human cytomegalovirus mutant with the UL18 (class I homolog) gene deleted. J. Virol. 66: 6784-6787.
33. Dolan, A., C. Cunningham, R. D. Hector, A. F. Hassan-Walker, L. Lee, C. Addison, D. J. Dargan, D. J. McGeoch, D. Gatherer, V. C. Emery, et al. 2004. Genetic content of wild-type human cytomegalovirus. J. Gen. Virol. 85: 1301-1312. (Pubitemid 38659794)
34. Cunningham, C., D. Gatherer, B. Hilfrich, K. Baluchova, D. J. Dargan, M. Thomson, P. D. Griffiths, G. W. Wilkinson, T. F. Schulz, and A. J. Davison. 2010. Sequences of complete human cytomegalovirus genomes from infected cell cultures and clinical specimens. J. Gen. Virol. 91: 605-615.
35. Stanton, R. J., K. Baluchova, D. J. Dargan, C. Cunningham, O. Sheehy, S. Seirafian, B. P. McSharry, M. L. Neale, J. A. Davies, P. Tomasec, et al. 2010. Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. J. Clin. Invest. 120: 3191-3208.
36. McSharry, B. P., C. J. Jones, J. W. Skinner, D. Kipling, and G. W. Wilkinson. 2001. Human telomerase reverse transcriptase-immortalized MRC-5 and HCA2 human fibroblasts are fully permissive for human cytomegalovirus. J. Gen. Virol. 82: 855-863. (Pubitemid 32280044)
37. Moins-Teisserenc, H. T., S. D. Gadola, M. Cella, P. R. Dunbar, A. Exley, N. Blake, C. Baykal, J. Lambert, P. Bigliardi, M. Willemsen, et al. 1999. Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules. [Published erratum appears in 2000 Lancet 356: 170.] Lancet 354: 1598-1603. (Pubitemid 29515952)
38. Jadot, M., M. W. Hofmann, R. Graf, H. Quader, and B. Martoglio. 1995. Protein insertion into the endoplasmic reticulum of permeabilized cells. FEBS Lett. 371: 145-148.
39. Martoglio, B., and B. Dobberstein. 1998. Signal sequences: more than just greasy peptides. Trends Cell Biol. 8: 410-415. (Pubitemid 28458707)
40. Weihofen, A., M. K. Lemberg, H. L. Ploegh, M. Bogyo, and B. Martoglio. 2000. Release of signal peptide fragments into the cytosol requires cleavage in the transmembrane region by a protease activity that is specifically blocked by a novel cysteine protease inhibitor. J. Biol. Chem. 275: 30951-30956.
41. Lemberg, M. K., and B. Martoglio. 2003. Analysis of polypeptides by sodium dodecyl sulfate-polyacrylamide gel electrophoresis alongside in vitro-generated reference peptides. Anal. Biochem. 319: 327-331. (Pubitemid 36842745)
42. Strong, R. K., M. A. Holmes, P. Li, L. Braun, N. Lee, and D. E. Geraghty. 2003. HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities. J. Biol. Chem. 278: 5082-5090. (Pubitemid 36801018)
43. Garrigue, I., M. Faure-Della Corte, N. Magnin, P. Recordon-Pinson, L. Couzi, M. E. Lebrette, M. H. Schrive, L. Roncin, J. L. Taupin, J. Déchanet-Merville, et al. 2008. UL40 human cytomegalovirus variability evolution patterns over time in renal transplant recipients. Transplantation 86: 826-835.
44. Cerboni, C., M. Mousavi-Jazi, H. Wakiguchi, E. Carbone, K. Kärre, and K. Söderström. 2001. Synergistic effect of IFN-gamma and human cytomegalovirus protein UL40 in the HLA-E-dependent protection from NK cellmediated cytotoxicity. Eur. J. Immunol. 31: 2926-2935. (Pubitemid 32994544)
45. Hartmann, E., T. A. Rapoport, and H. F. Lodish. 1989. Predicting the orientation of eukaryotic membrane-spanning proteins. Proc. Natl. Acad. Sci. USA 86: 5786-5790. (Pubitemid 19217538)
46. Wei, M. L., and P. Cresswell. 1992. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 356: 443-446.
47. von Heijne, G. 1985. Ribosome-SRP-signal sequence interactions. The relay helix hypothesis. FEBS Lett. 190: 1-5.
48. Griffin, C., E. C. Wang, B. P. McSharry, C. Rickards, H. Browne, G. W. Wilkinson, and P. Tomasec. 2005. Characterization of a highly glycosylated form of the human cytomegalovirus HLA class I homologue gpUL18. J. Gen. Virol. 86: 2999-3008. (Pubitemid 41555564)
49. Park, B., H. Oh, S. Lee, Y. Song, J. Shin, Y. C. Sung, S. Y. Hwang, and K. Ahn. 2002. The MHC class I homolog of human cytomegalovirus is resistant to downregulation mediated by the unique short region protein (US)2, US3, US6, and US11 gene products. J. Immunol. 168: 3464-3469. (Pubitemid 34250412)
50. Millo, E., G. Pietra, A. Armirotti, P. Vacca, M. C. Mingari, L. Moretta, and G. Damonte. 2007. Purification and HPLC-MS analysis of a naturally processed HCMV-derived peptide isolated from the HEK-293T/HLA-E+/Ul40+ cell transfectants and presented at the cell surface in the context of HLA-E. J. Immunol. Methods 322: 128-136. (Pubitemid 46562519)
51. Schrul, B., K. Kapp, I. Sinning, and B. Dobberstein. 2010. Signal peptide peptidase (SPP) assembles with substrates and misfolded membrane proteins into distinct oligomeric complexes. Biochem. J. 427: 523-534.
52. Henderson, R. A., H. Michel, K. Sakaguchi, J. Shabanowitz, E. Appella, D. F. Hunt, and V. H. Engelhard. 1992. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science 255: 1264-1266.
53. Kapp, K., S. Schrempf, M. K. Lemberg, and B. Dobberstein. 2009. Posttargeting functions of signal peptides. In Protein Transport into the Endoplasmic Reticulum. R. Zimmermann, ed. Landes Bioscience, Austin, TX, p. 913-918.
54. Nattermann, J., H. D. Nischalke, V. Hofmeister, G. Ahlenstiel, H. Zimmermann, L. Leifeld, E. H. Weiss, T. Sauerbruch, and U. Spengler. 2005. The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells. Am. J. Pathol. 166: 443-453. (Pubitemid 40189041)
55. Nattermann, J., H. D. Nischalke, V. Hofmeister, B. Kupfer, G. Ahlenstiel, G. Feldmann, J. Rockstroh, E. H. Weiss, T. Sauerbruch, and U. Spengler. 2005. HIV-1 infection leads to increased HLA-E expression resulting in impaired function of natural killer cells. Antivir. Ther. (Lond.) 10: 95-107. (Pubitemid 40767635)
56. Hoare, H. L., L. C. Sullivan, C. S. Clements, L. K. Ely, T. Beddoe, K. N. Henderson, J. Lin, H. H. Reid, A. G. Brooks, and J. Rossjohn. 2008. Subtle changes in peptide conformation profoundly affect recognition of the nonclassical MHC class I molecule HLA-E by the CD94-NKG2 natural killer cell receptors. J. Mol. Biol. 377: 1297-1303.
57. Kaiser, B. K., F. Barahmand-Pour, W. Paulsene, S. Medley, D. E. Geraghty, and R. K. Strong. 2005. Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. J. Immunol. 174: 2878-2884. (Pubitemid 40279705)
58. Sullivan, L. C., C. S. Clements, T. Beddoe, D. Johnson, H. L. Hoare, J. Lin, T. Huyton, E. J. Hopkins, H. H. Reid, M. C. Wilce, et al. 2007. The heterodimeric assembly of the CD94-NKG2 receptor family and implications for human leukocyte antigen-E recognition. Immunity 27: 900-911. (Pubitemid 50013980)
59. Magri, G., A. Muntasell, N. Romo, A. Sáez-Borderías, D. Pende, D. E. Geraghty, H. Hengel, A. Angulo, A. Moretta, and M. López-Botet. 2011. NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirusinfected myeloid dendritic cells overcoming viral immune evasion strategies. Blood 117: 848-856.
60. Chapman, T. L., and P. J. Bjorkman. 1998. Characterization of a murine cytomegalovirus class I major histocompatibility complex (MHC) homolog: comparison to MHC molecules and to the human cytomegalovirus MHC homolog. J. Virol. 72: 460-466. (Pubitemid 28048859)
61. Kim, Y., B. Park, S. Cho, J. Shin, K. Cho, Y. Jun, and K. Ahn. 2008. Human cytomegalovirus UL18 utilizes US6 for evading the NK and T-cell responses. PLoS Pathog. 4: e1000123.
62. Khan, A. R., B. M. Baker, P. Ghosh, W. E. Biddison, and D. C. Wiley. 2000. The structure and stability of an HLA-A*0201/octameric tax peptide complex with an empty conserved peptide-N-terminal binding site. J. Immunol. 164: 6398-6405. (Pubitemid 30408822)
63. Glithero, A., J. Tormo, K. Doering, M. Kojima, E. Y. Jones, and T. Elliott. 2006. The crystal structure of H-2D(b) complexed with a partial peptide epitope suggests a major histocompatibility complex class I assembly intermediate. J. Biol. Chem. 281: 12699-12704. (Pubitemid 43855360)
64. Kaiser, B. K., J. C. Pizarro, J. Kerns, and R. K. Strong. 2008. Structural basis for NKG2A/CD94 recognition of HLA-E. Proc. Natl. Acad. Sci. USA 105: 6696-6701. (Pubitemid 351754569)